GlobeNewswire by notified

Ageas reports full-year results 2023

Share

Ageasreportsfull-yearresults 2023

  • Excellent commercial performance in Non-Life across all segments and double-digit growth in Life in China
  • Net Operating Result at EUR 1,166 million, reflected by an excellent Operational Capital Generation
  • Cash position increased significantly to EUR 959 million
  • Proposed total dividend of EUR 3.25 per share, up more than 8%. Final dividend of EUR 1.75 per share
KeyFigures (Group)
Result
  • Net Operating Result of EUR 1,166 million, representing a 16.2 %Return on Equity
  • Net Result of EUR953 million
  • Operational Capital Generation of EUR1,803 million
  • Operational Free Capital Generation of EUR 1,162 million
Inflows
(at constant exchange rate)
  • Inflows grew 8% at constant exchange rates, amounting to EUR 17.1 billion driven by the excellent commercial performance in Non-Life and strong sales in Life in China
  • Life inflows stood at EUR 11.2 billion with lower inflows in Belgium and Europe, compensated by growth in Asia
  • Non-Life inflows grew 17 % at constant exchange rates and stood at EUR 5.9 billion thanks to increases across all segments
OperatingPerformance
  • Combined ratio of 93.3%,
    • Guaranteed Margin of 124 bps and Unit Linked Margin of 39 bps
BalanceSheet
  • Comprehensive Equity of EUR 15.6 billion or EUR 85.04 per share
  • Pillar II Solvency II ratio improved, reaching 217%, well above the Group’s risk appetite
  • General account Total Liquid Assets as at 31 December 2023 stood at EUR 959 million
  • Life Liabilities excl. UG/L stood at EUR 84.7 billion

An overviewofthefiguresandcomparisonwithpreviousyearcanbefoundonpage7 ofthispressreleaseandontheAgeaswebsite.

Impact24 -- Non-financial and Sustainability Achievements



  • Due to the continued sustainability efforts throughout the company, Ageas improved its ratings with five out of the six ESG rating agencies that follow the Group.
  • Several Group entities were awarded for their efforts in the field of Human Resources, which supports Ageas’s ambition to be a “Great place to Grow” for its employees.
  • Ageas introduced several initiatives to strengthen its core business and distribution channels, improve customer experience, and integrate new technologies.

Hans De Cuyper, CEO Ageas, commented: “In 2023, we delivered a strong commercial performance. This was mainly driven by a remarkable growth in Non-Life across the Group and by the strong Life activities in China, while Reinsurance also successfully concluded its 1 January 2024 renewal campaign. The solid margins in Life and the strong combined ratio in Non-Life confirm the operational strength of our business now and going forward. In meeting our commitments with regards to the Net Operating Result, we are proud to announce a total gross cash dividend of EUR 3.25 over 2023, in line with our engagement under Impact24. Regarding the progress on our Impact24 strategy, again in 2023, we took important steps in delivering on our ambitions in terms of growth, commercial excellence, integration of tech & data, and sustainability. As a result, we made good progress against our non-financial and sustainability targets on many fronts, which was also recognised by the outside world, as evidenced by the rating increase throughout the year by five of the six ESG rating agencies that follow us. I’m very grateful to our dedicated people and valued partners for their significant contributions to our strong performance in 2023, and I want to thank our investors and customers for their unwavering trust in our company.”

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Idorsia publishes a Financial Status required for an upcoming bondholder meeting17.4.2024 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company websiteBondholder meeting now planned for early May as the company continues to engage with bondholders Allschwil, Switzerland – April 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting is available on the company website at the following link: http://www.idorsia.com/investors/financial-information Idorsia continues to engage with bondholders on options and terms regarding the repayment of the convertible bond maturing on July 17, 2024 (ISIN: CH0426820350). As a result, the bondholder meeting initially contemplated for April 30, 2024, is expected to take place shortly thereafter. André C. Muller, Chief Financial Officer, commented: “We have had many interactions with our bondholders in the past week. We are finalizing our pr

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis17.4.2024 07:00:00 CEST | Press release

New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS Paris, April 17, 2024. Sanofi’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis. These data will be presented today at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, Colorado, US. Results from the 12-week double-blind study period were previously published in The New England Journal of Medicine. Patrick Vermersch, MD, PhD University of Lille,

TokenEx and IXOPAY to Merge, Enabling Merchants to Optimize the Use of Multiple Payment Processors17.4.2024 06:00:00 CEST | Press release

Payments Optimization Platform for Global Commerce Delivers Omnichannel Tokenization, Payments Orchestration, and Card Lifecycle Management TULSA, Okla. and VIENNA, Austria, April 17, 2024 (GLOBE NEWSWIRE) -- TokenEx, the leading cloud tokenization provider, and IXOPAY, the leading independent payments orchestration platform, today are announcing their definitive agreement to merge, creating a new leader in global payments optimization. The combined company will be called IXOPAY, a TokenEx Company, and Marc Olesen will lead the combined organization as CEO. Customers will benefit from a comprehensive platform that enables increased authorization rates and decreased interchange fees for merchants, along with PCI-certified secure payment data. This merger brings together the strengths of TokenEx’s expertise in tokenization of payment data, and IXOPAY's world-class payments orchestration, including transaction routing & reconciliation capabilities. “This merger marks a significant milesto

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders17.4.2024 02:00:00 CEST | Press release

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders MILLICOM INTERNATIONAL CELLULAR S.A. Registered Address: 2, Rue du Fort Bourbon L-1249 Luxembourg, Grand Duchy of Luxembourg – R.C.S. Luxembourg: B 40.630 – I. NOTICE The annual general meeting (“AGM”) and subsequent extraordinary general meeting (“EGM”) of the shareholders of MILLICOM INTERNATIONAL CELLULAR S.A. (“Millicom” or the “Company”) is hereby convened to be held at Hotel Le Royal, 12 Bd Royal, 2449 Luxembourg on Thursday, May 23, 2024, at 11:00 a.m. Central European Time ("CET"). To attend the AGM and EGM or vote by proxy, please follow the instructions in section IV: “Right to participate at the AGM and the EGM”. The AGM and EGM will consider and vote on the agenda points listed below. Please refer to section IX: “Notes to the Agenda Points of the AGM and EGM” to find detailed information about these proposals. II. AGENDA AGM To elect the chair of the AGM and to empower the chair of

Millicom’s Nomination Committee’s proposal for Board of Directors17.4.2024 02:00:00 CEST | Press release

Millicom’s Nomination Committee’s proposal for Board of Directors Luxembourg, April 17, 2024 – In advance of the Annual General Meeting of shareholders (“AGM”) of Millicom International Cellular S.A. (“Millicom”), to be held on May 23, 2024, Millicom’s Nomination Committee proposes: The election of Maxime Lombardini and Justine Dimovic as new Directors of the Board; The re-election of María Teresa Arnal Machado, Bruce Churchill, Aude Durand, Tomas Eliasson, Mauricio Ramos, Thomas Reynaud, and Blanca Treviño de Vega as Directors of the Board; and the election of Mauricio Ramos as Chair of the Board. Pernille Erenbjerg and Michael Golan have decided not to seek re-election. Maxime Lombardini will bring his extensive experience and track record in leading businesses in the telecommunications industry, as well as the strong knowledge of Millicom that he has gained while serving as President and Chief Operating Officer since September 2023. Justine Dimovic will bring a wealth of capital all

HiddenA line styled icon from Orion Icon Library.Eye